Viatris is a global healthcare company whose mission is to empower people worldwide to live healthier at every stage of life. The company supplies high quality medicines to approximately one billion patients each year across more than 165 countries and territories. Viatris operates a diversified portfolio that includes generic medicines, branded products, over the counter items and an expanding range of innovative medicines. It maintains a presence in 27 manufacturing packaging and distribution sites spread over five continents and employs more than 30 000 people. The company’s product library consists of more than 1 400 approved molecules spanning numerous therapeutic areas such as cardiovascular health oncology infectious diseases and central nervous system disorders. Viatris is headquartered in the United States with additional global centers in Pittsburgh Pennsylvania Shanghai China and Hyderabad India.

Viatris generates revenue primarily through the sale of its pharmaceutical products to wholesalers distributors retailers hospitals and government agencies. The company’s revenue streams consist of sales of generic drugs which include both simple and complex formulations such as biosimilars and specialty generics. Branded products contribute another significant portion of sales including well known names that are either protected by patent or marketed as branded generics. Over the counter medicines are sold directly to consumers through retail channels and add to the total turnover. In addition Viatris earns income from licensing agreements collaborations and royalty arrangements that allow other firms to use its intellectual property or manufacturing capabilities. The company also benefits from contract manufacturing and supply agreements that provide services to third parties while leveraging its own production network. Overall the mix of geographic reach product diversity and contractual relationships supports a steady flow of income.

Within the pharmaceutical industry Viatris occupies a prominent position as one of the largest providers of generic medicines globally. It competes with major players such as Teva Pharmaceutical Industries Sandoz a division of Novartis and various regional generic manufacturers. The company’s competitive advantages stem from its extensive global manufacturing footprint its integrated supply chain that can move products across borders efficiently and its broad therapeutic portfolio that reduces reliance on any single product or market. Viatris also emphasizes research and development efforts focused on complex generics biosimilars and novel patent protected assets which helps differentiate its offerings from pure commodity players. Its scale enables cost advantages in procurement and distribution while its regulatory expertise supports timely approvals in multiple jurisdictions. These factors together allow Viatris to maintain stable margins and to pursue growth opportunities in both established and emerging markets.

Viatris serves a varied customer base that includes large wholesale distributors retail pharmacy chains hospitals government health programs and institutional purchasers. Specific customers named in the filing are McKesson Corporation Cencora Inc and Cardinal Health Inc which represent significant portions of the company’s consolidated net sales. In addition to these major distributors the company supplies medicines to independent pharmacies long term care facilities clinics and various public health agencies. By serving both private sector and public sector clients Viatris ensures its products reach a wide spectrum of patients through multiple channels of the healthcare system.